Ginkgo Advisory · Insights

Neonatal Phototherapy Systems: UK MHRA CFS, Registration and Apostille

Ginkgo Advisory

A UK MHRA Certificate of Free Sale (CFS) for neonatal phototherapy systems supports overseas dossiers for registered light-treatment equipment. Its schedule links selected phototherapy products to the manufacturer’s intended-purpose descriptions, optical specifications and conformity documentation.

The issued certificate can then be prepared for overseas use through verification, professional certification, an apostille and any required embassy legalisation.

Product category and MHRA registration: Neonatal Phototherapy Systems

Neonatal phototherapy systems are general medical devices intended to deliver specified light for the treatment of neonatal jaundice within the manufacturer’s clinical application. Product designs can include overhead light units or systems delivering light through a pad or other documented patient interface. The intended purpose defines the newborn patient population, intended users and operating environment for each system.

The MHRA’s Device Online Registration System, or DORS, holds manufacturer, device and product records. Registration includes the relevant conformity information, such as CE or UKCA documentation, together with the details identifying the products. For manufacturers based outside the UK, a UK Responsible Person represents the manufacturer for the Great Britain registration process.

The MHRA’s medical device registration guidance explains the registration framework. The April 2026 reference guide describes how these records are entered and maintained in the online system.

For Great Britain, the manufacturer’s records sit within the UK medical device framework. A CFS order is submitted by an eligible UK-based manufacturer or UK Responsible Person, using registered products and the relevant CE or UKCA conformity evidence.

Documents and product information

The registration process brings together information about the manufacturer, the product and its conformity documentation. The main records include:

  • Manufacturer details: the legal manufacturer’s name, registered address and contact information.
  • UK Responsible Person documentation: representative details and the designation agreement, where applicable.
  • Product details: system name, model, catalogue reference, legal manufacturer, light-source type, delivery arrangement, treatment-area specification and supplied controls. Labels, instructions, conformity documents and technical-file records describe wavelength characteristics, irradiance performance, operating modes, electrical safety and relevant thermal considerations. Documentation identifies the supplied stand, light-delivery components, cleaning requirements and any compatible covers or other patient-contact items.
  • Registration identifiers: the GMDN code and term, with Basic UDI-DI and UDI-DI where applicable.
  • Conformity documentation: the Declaration of Conformity and applicable conformity assessment certificates, including their references, validity and product schedules.
  • Supporting product records: labels, instructions for use and the technical and performance documentation held by the manufacturer.

The online registration links the relevant conformity documents to the device record and identifies the individual products beneath it. The wider technical documentation supports the manufacturer’s compliance records; it is not a separate standard upload package for each CFS order.

From MHRA registration to an electronic CFS

  1. Accepted registration establishes the manufacturer, device and individual product records in DORS. Current conformity documents are linked to the relevant entries.
  2. The applicant selects the products marked CFS Ready and reviews the certificate and schedule preview. Model names and catalogue references come from the registered product data.
  3. After the order is submitted and paid for, the MHRA issues an electronically signed PDF. The complete certificate and every schedule page form the document set for subsequent verification and legalisation.

The MHRA CFS Reference Guide describes these stages. The published CFS service information gives an issuance aim of ten working days, with longer processing possible during busy periods.

Product coverage in the CFS schedule

A phototherapy range may contain different light-unit sizes, output configurations and pad arrangements under one brand. The registered descriptions distinguish the products selected for the CFS and connect them to their respective technical records. Replacement light-delivery pads, stands or covers can carry separate catalogue references and applicable product identities. An incubator used alongside a phototherapy unit retains its own documented scope. Complete schedule pages and component descriptions help the overseas recipient identify whether the certificate represents an overhead unit, a pad-based system or specifically listed accompanying products.

Direct verification of the CFS with the MHRA

For an overseas submission, the authenticity of the issued certificate is an important part of document preparation. Ginkgo Advisory can arrange for a solicitor to seek direct confirmation of the CFS with the MHRA and review the certificate together with its schedule.

Solicitor certification and express UK FCDO apostille

Where the solicitor-certified route is accepted for the intended submission, Ginkgo Advisory can arrange solicitor certification followed by a UK FCDO paper apostille. The certification format is matched to the receiving authority’s requirements. MHRA’s published guidance describes a notarial route, and notarisation is arranged where that route is required.

Our express UK FCDO apostille service normally takes two working days once verification and the required certification are complete and the document is accepted for submission. The apostille stage has its own timetable, separate from MHRA certificate issuance, verification responses, any embassy processing and delivery. Further FCDO checks can affect completion.

Embassy legalisation for Egypt, the UAE, Kuwait and Qatar

Ginkgo Advisory can arrange embassy legalisation where required, bringing the verification, certification, apostille and relevant embassy submission into one coordinated service. The destination and intended use determine the required document format and any additional stages.

Preparing an issued MHRA CFS for overseas use

For a quotation, the starting documents are the MHRA-issued electronic PDF and all accompanying schedule pages. The issuance email, destination country, receiving authority’s instructions and required completion date help establish the appropriate preparation and delivery arrangements.

Contact Ginkgo Advisory with the issued CFS for a quotation covering direct MHRA verification, solicitor certification where accepted, express FCDO apostille and any required embassy legalisation.

Product questions

Does a phototherapy CFS also include the incubator used with the light unit?

The phototherapy system and incubator have their own product descriptions and supporting records. Their use together does not establish shared certificate coverage. The selected registered entries and issued schedule identify which systems and accompanying products are actually included in the certificate set.

MHRA reference guides